High expression of 5-hydroxymethylcytosine and isocitrate dehydrogenase 2 is associated with favorable prognosis after curative resection of hepatocellular carcinoma

BackgroundThe expression of 5-hydroxymethylcytosine (5-hmC) and isocitrate dehydrogenase 2 (IDH2) is frequently downregulated in numerous cancers. 5-hmC and IDH2 expression in hepatocellular carcinoma (HCC) has yet to be determined.MethodsThe immunohistochemical expression of 5-hmC and IDH2 were analyzed in tissue microarrays containing samples from 646 patients who had undergone hepatectomy for histologically proven HCC. The prognostic value of 5-hmC and IDH2 were evaluated by Cox regression and Kaplan-Meier analyses.ResultsWe discovered that low 5-hmC and IDH2 expression was associated with malignant behaviors. Low 5-hmC or IDH2 expression alone and combined 5-hmC and IDH2 expression were associated with lower overall survival (OS) rates and higher cumulative recurrence rates. Multivariate analysis indicated that 5-hmC or IDH2 and 5-hmC/IDH2 were independent prognostic indicators for OS and time to recurrence (TTR), which was confirmed in an independent validation cohort.Conclusions5-hmC and IDH2 correlate with less aggressive tumor behavior in HCC. When 5-hmC and IDH2 are considered together, they serve as a prognostic marker in patients with surgically resected HCCs.

[1]  A. Covey,et al.  Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma , 2012, CA: a cancer journal for clinicians.

[2]  He Huang,et al.  Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China , 2013, Proceedings of the National Academy of Sciences.

[3]  W. Nelson,et al.  Decreased 5-Hydroxymethylcytosine Is Associated with Neural Progenitor Phenotype in Normal Brain and Shorter Survival in Malignant Glioma , 2012, PloS one.

[4]  W. Yung,et al.  IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma. , 2013, Neuro-oncology.

[5]  M. Esteller,et al.  Aberrant epigenetic landscape in cancer: how cellular identity goes awry. , 2010, Developmental cell.

[6]  Isabel B. Lokody.  Metabolism: IDH2 drives cancer in vivo , 2013, Nature Reviews Cancer.

[7]  A. Gambotto,et al.  Expression of X‐linked inhibitor‐of‐apoptosis protein in hepatocellular carcinoma promotes metastasis and tumor recurrence , 2008, Hepatology.

[8]  D. Woodfield.  Hepatocellular carcinoma. , 1986, The New Zealand medical journal.

[9]  Z. Wang,et al.  Isocitrate dehydrogenase 1 (IDH1) mutation-specific microRNA signature predicts favorable prognosis in glioblastoma patients with IDH1 wild type , 2013, Journal of experimental & clinical cancer research : CR.

[10]  Zhao-You Tang,et al.  Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  S. Qiu,et al.  High expression of IL-17 and IL-17RE associate with poor prognosis of hepatocellular carcinoma , 2013, Journal of experimental & clinical cancer research : CR.

[12]  J. Llovet,et al.  Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies , 2013, Oncogene.

[13]  G. Schackert,et al.  5-Hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations. , 2011, Cancer research.

[14]  A. Grigoriadis,et al.  IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours , 2011, The Journal of pathology.

[15]  Yi Zhang,et al.  Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification , 2010, Nature.

[16]  David R. Liu,et al.  Conversion of 5-Methylcytosine to 5- Hydroxymethylcytosine in Mammalian DNA by the MLL Partner TET1 , 2009 .

[17]  H. Leonhardt,et al.  Sensitive enzymatic quantification of 5-hydroxymethylcytosine in genomic DNA , 2010, Nucleic acids research.

[18]  Jung-Il Lee,et al.  Clinicopathologic and genomic features of gliosarcomas , 2012, Journal of Neuro-Oncology.

[19]  Corbin E. Meacham,et al.  Tumour heterogeneity and cancer cell plasticity , 2013, Nature.

[20]  Feng-Chun Yang,et al.  Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. , 2011, Blood.

[21]  Q. Ye,et al.  Positive serum hepatitis B e antigen is associated with higher risk of early recurrence and poorer survival in patients after curative resection of hepatitis B-related hepatocellular carcinoma. , 2007, Journal of hepatology.

[22]  N. Heintz,et al.  The Nuclear DNA Base 5-Hydroxymethylcytosine Is Present in Purkinje Neurons and the Brain , 2009, Science.

[23]  K. Kinzler,et al.  Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome , 2011, Proceedings of the National Academy of Sciences.

[24]  Peter A. Jones,et al.  Cancer genetics and epigenetics: two sides of the same coin? , 2012, Cancer cell.

[25]  Fan Shen,et al.  Quantification of 5-methylcytosine and 5-hydroxymethylcytosine in genomic DNA from hepatocellular carcinoma tissues by capillary hydrophilic-interaction liquid chromatography/quadrupole TOF mass spectrometry. , 2013, Clinical chemistry.

[26]  M. Dawson,et al.  Cancer Epigenetics: From Mechanism to Therapy , 2012, Cell.

[27]  H. Aburatani,et al.  Loss of 5‐hydroxymethylcytosine is accompanied with malignant cellular transformation , 2012, Cancer science.

[28]  J. Kinoshita,et al.  Adiponectin receptor-1 expression is associated with good prognosis in gastric cancer , 2011, Journal of experimental & clinical cancer research : CR.

[29]  Regulation of microRNAs by epigenetics and their interplay involved in cancer , 2013, Journal of experimental & clinical cancer research : CR.

[30]  Abraham J. Khorasani,et al.  Loss of 5-Hydroxymethylcytosine Is an Epigenetic Hallmark of Melanoma , 2012, Cell.

[31]  Fang Wang,et al.  Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation , 2013, Science.

[32]  Bin Wang,et al.  Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. , 2011, Cancer cell.

[33]  M. Esteller,et al.  Cancer epigenetics reaches mainstream oncology , 2011, Nature Medicine.

[34]  S. Qiu,et al.  Association of autophagy defect with a malignant phenotype and poor prognosis of hepatocellular carcinoma. , 2008, Cancer research.

[35]  Z. Ling,et al.  Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation , 2013, Oncogene.